{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:46:46Z","timestamp":1787755606697,"version":"build-2784847793"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:00:00Z","timestamp":1766793600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:00:00Z","timestamp":1766793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82401636"],"award-info":[{"award-number":["82401636"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s10067-025-07896-w","type":"journal-article","created":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T02:57:29Z","timestamp":1766804249000},"page":"2009-2021","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Muscle expression of PD1 and PD-L1 may predict the severity and outcomes of neuromuscular immune-related adverse events caused by immune checkpoint inhibitor treatment"],"prefix":"10.1007","volume":"45","author":[{"given":"Mengting","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7585-3329","authenticated-orcid":false,"given":"Yawen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,27]]},"reference":[{"key":"7896_CR1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","volume":"62","author":"KM Hargadon","year":"2018","unstructured":"Hargadon KM, Johnson CE, Williams CJ (2018) Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol 62:29\u201339","journal-title":"Int Immunopharmacol"},{"issue":"10304","key":"7896_CR2","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","volume":"398","author":"MS Carlino","year":"2021","unstructured":"Carlino MS, Larkin J, Long GV (2021) Immune checkpoint inhibitors in melanoma. Lancet 398(10304):1002\u20131014","journal-title":"Lancet"},{"issue":"21","key":"7896_CR3","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","volume":"184","author":"G Morad","year":"2021","unstructured":"Morad G, Helmink BA, Sharma P, Wargo JA (2021) Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 184(21):5309\u20135337","journal-title":"Cell"},{"issue":"9","key":"7896_CR4","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei SC, Duffy CR, Allison JP (2018) Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 8(9):1069\u20131086","journal-title":"Cancer Discov"},{"issue":"5","key":"7896_CR5","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","volume":"83","author":"AN Geisler","year":"2020","unstructured":"Geisler AN, Phillips GS, Barrios DM, Wu J, Leung DYM, Moy AP et al (2020) Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol 83(5):1255\u201368","journal-title":"J Am Acad Dermatol"},{"key":"7896_CR6","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinph.2025.2110989","volume":"179","author":"E Lainez","year":"2025","unstructured":"Lainez E, Llaurad\u00f3 A, Gratac\u00f2s-Vi\u00f1ola M, Seoane JL, Trallero-Aragu\u00e1s E, Ari\u00f1o H et al (2025) Electrophysiological findings in immune checkpoint inhibitor-related neuromuscular events. Clin Neurophysiol 179:2110989","journal-title":"Clin Neurophysiol"},{"issue":"4","key":"7896_CR7","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s00415-023-12134-x","volume":"271","author":"A Vicino","year":"2024","unstructured":"Vicino A, Hottinger AF, Latifyan S, Boughdad S, Becce F, Prior JO et al (2024) Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series. J Neurol 271(4):1947\u20131958","journal-title":"J Neurol"},{"issue":"4","key":"7896_CR8","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.7722","volume":"5","author":"MZ Farooq","year":"2022","unstructured":"Farooq MZ, Aqeel SB, Lingamaneni P, Pichardo RC, Jawed A, Khalid S et al (2022) Association of immune checkpoint inhibitors with neurologic adverse events: a systematic review and meta-analysis. JAMA Netw Open 5(4):e227722","journal-title":"JAMA Netw Open"},{"issue":"6","key":"7896_CR9","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/ajco.13375","volume":"16","author":"S Fan","year":"2020","unstructured":"Fan S, Ren H, Zhao L, Yin J, Feng G, Wang J et al (2020) Neurological immune-related adverse events associated with immune checkpoint inhibitors: a review of the literature. Asia Pac J Clin Oncol 16(6):291\u20138","journal-title":"Asia Pac J Clin Oncol"},{"issue":"16","key":"7896_CR10","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1212\/WNL.0000000000011795","volume":"96","author":"A Marini","year":"2021","unstructured":"Marini A, Bernardini A, Gigli GL, Valente M, Mu\u00f1iz-Castrillo S, Honnorat J et al (2021) Neurologic adverse events of immune checkpoint inhibitors: a systematic review. Neurology 96(16):754\u2013766","journal-title":"Neurology"},{"issue":"14","key":"7896_CR11","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1212\/WNL.0000000000007235","volume":"92","author":"A Johansen","year":"2019","unstructured":"Johansen A, Christensen SJ, Scheie D, H\u00f8jgaard JLS, Kondziella D (2019) Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: systematic review. Neurology 92(14):663\u2013674","journal-title":"Neurology"},{"issue":"11","key":"7896_CR12","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000210031","volume":"103","author":"G Beecher","year":"2024","unstructured":"Beecher G, Pinal-Fernandez I, Mammen AL, Liewluck T (2024) Immune checkpoint inhibitor myopathy: the double-edged sword of cancer immunotherapy. Neurology 103(11):e210031","journal-title":"Neurology"},{"issue":"9","key":"7896_CR13","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41582-024-01001-6","volume":"20","author":"M O'Hare","year":"2024","unstructured":"O\u2019Hare M, Guidon AC (2024) Peripheral nervous system immune-related adverse events due to checkpoint inhibition. Nat Rev Neurol 20(9):509\u201325","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"7896_CR14","doi-asserted-by":"crossref","first-page":"e985","DOI":"10.1212\/WNL.0000000000006124","volume":"91","author":"M Touat","year":"2018","unstructured":"Touat M, Maisonobe T, Knauss S, Ben Hadj Salem O, Hervier B, Aur\u00e9 K et al (2018) Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology 91(10):e985\u2013e994","journal-title":"Neurology"},{"issue":"4","key":"7896_CR15","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00415-011-6193-8","volume":"259","author":"G Meola","year":"2012","unstructured":"Meola G, Bugiardini E, Cardani R (2012) Muscle biopsy. J Neurol 259(4):601\u2013610","journal-title":"J Neurol"},{"issue":"3","key":"7896_CR16","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.pmr.2012.06.006","volume":"23","author":"NC Joyce","year":"2012","unstructured":"Joyce NC, Oskarsson B, Jin LW (2012) Muscle biopsy evaluation in neuromuscular disorders. Phys Med Rehabil Clin N Am 23(3):609\u201331","journal-title":"Phys Med Rehabil Clin N Am"},{"issue":"7","key":"7896_CR17","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/jnen\/nlaa046","volume":"79","author":"JS Nix","year":"2020","unstructured":"Nix JS, Moore SA (2020) What every neuropathologist needs to know: the muscle biopsy. J Neuropathol Exp Neurol 79(7):719\u2013733","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"7896_CR18","volume":"12","author":"K Mukund","year":"2020","unstructured":"Mukund K, Subramaniam S (2020) Skeletal muscle: a review of molecular structure and function, in health and disease. Wiley Interdiscip Rev Syst Biol Med 12(1):e1462","journal-title":"Wiley Interdiscip Rev Syst Biol Med"},{"issue":"5","key":"7896_CR19","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/sms.12808","volume":"27","author":"B Ekblom","year":"2017","unstructured":"Ekblom B (2017) The muscle biopsy technique. Historical and methodological considerations. Scand J Med Sci Sports 27(5):458\u2013461","journal-title":"Scand J Med Sci Sports"},{"issue":"2","key":"7896_CR20","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2478\/v10042-009-0066-3","volume":"47","author":"O Paciello","year":"2009","unstructured":"Paciello O, Papparella S (2009) Histochemical and immunohistological approach to comparative neuromuscular diseases. Folia Histochem Cytobiol 47(2):143\u2013152","journal-title":"Folia Histochem Cytobiol"},{"issue":"1","key":"7896_CR21","doi-asserted-by":"crossref","DOI":"10.1186\/s42466-020-00064-2","volume":"2","author":"HC Lehmann","year":"2020","unstructured":"Lehmann HC, Wunderlich G, Fink GR, Sommer C (2020) Diagnosis of peripheral neuropathy. Neurol Res Pract 2(1):20","journal-title":"Neurol Res Pract"},{"issue":"3","key":"7896_CR22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.medcli.2023.04.006","volume":"161","author":"DA Garc\u00eda Est\u00e9vez","year":"2023","unstructured":"Garc\u00eda Est\u00e9vez DA, Pardo Fern\u00e1ndez J (2023) Myasthenia gravis. Update on diagnosis and therapy. Med Clin (Barc) 161(3):119\u201327","journal-title":"Med Clin (Barc)"},{"issue":"2","key":"7896_CR23","first-page":"219","volume":"47","author":"S Suzuki","year":"2020","unstructured":"Suzuki S (2020) Myasthenia gravis and myositis(PD-1 myopathy). Gan to kagaku ryoho Cancer & chemotherapy 47(2):219\u2013223","journal-title":"Gan to kagaku ryoho Cancer & chemotherapy"},{"issue":"Suppl 2","key":"7896_CR24","first-page":"S74","volume":"24","author":"D Psimaras","year":"2019","unstructured":"Psimaras D, Velasco R, Birzu C, Tamburin S, Lustberg M, Bruna J et al (2019) Immune checkpoint inhibitors-induced neuromuscular toxicity: from pathogenesis to treatment. Journal of the peripheral nervous system\u202f: JPNS 24(Suppl 2):S74-s85","journal-title":"Journal of the peripheral nervous system : JPNS"},{"issue":"2","key":"7896_CR25","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102455","volume":"19","author":"A Matas-Garc\u00eda","year":"2020","unstructured":"Matas-Garc\u00eda A, Milisenda JC, Selva-O\u2019Callaghan A, Prieto-Gonz\u00e1lez S, Padrosa J, Cabrera C et al (2020) Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern. Autoimmun Rev 19(2):102455","journal-title":"Autoimmun Rev"},{"key":"7896_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002890","author":"AC Guidon","year":"2021","unstructured":"Guidon AC, Burton LB, Chwalisz BK, Hillis J, Schaller TH, Amato AA et al (2021) Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-002890","journal-title":"J Immunother Cancer"},{"issue":"3","key":"7896_CR27","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jaccao.2025.02.005","volume":"7","author":"O Itzhaki Ben Zadok","year":"2025","unstructured":"Itzhaki Ben Zadok O, O\u2019Hare MJ, Nohria A (2025) Immune checkpoint inhibitor-related myocarditis with or without concomitant myopathy: clinical findings and cardiovascular outcomes. JACC CardioOncol 7(3):252\u201364","journal-title":"JACC CardioOncol"},{"key":"7896_CR28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115707","volume":"228","author":"AM Di Giacomo","year":"2025","unstructured":"Di Giacomo AM, Bartalini S, D\u2019Alonzo V, Cerase A, Cutarella S, Rossi G et al (2025) Neurological adverse events of ICI therapy: a ten-year comprehensive management from a multidisciplinary team. European journal of cancer (Oxford, England\u202f: 1990) 228:115707","journal-title":"European journal of cancer (Oxford, England : 1990)"},{"key":"7896_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11216566","author":"M Yang","year":"2022","unstructured":"Yang M, Ji S, Xu L, Zhang Q, Li Y, Gao H et al (2022) The clinicopathological distinction between immune-mediated necrotizing myopathy and limb-girdle muscular dystrophy R2: key points to prevent misdiagnosis. J Clin Med. https:\/\/doi.org\/10.3390\/jcm11216566","journal-title":"J Clin Med"},{"key":"7896_CR30","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13023-015-0277-y","volume":"10","author":"S Suzuki","year":"2015","unstructured":"Suzuki S, Nishikawa A, Kuwana M, Nishimura H, Watanabe Y, Nakahara J et al (2015) Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients. Orphanet J Rare Dis 10:61","journal-title":"Orphanet J Rare Dis"},{"key":"7896_CR31","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8865054","volume":"2020","author":"N M\u00f6hn","year":"2020","unstructured":"M\u00f6hn N, Mahjoub S, Gutzmer R, Satzger I, Beutel G, Ivanyi P et al (2020) Diagnosis and differential diagnosis of neurological adverse events during immune checkpoint inhibitor therapy. J Oncol 2020:8865054","journal-title":"J Oncol"},{"issue":"1","key":"7896_CR32","volume":"7","author":"DB Johnson","year":"2019","unstructured":"Johnson DB, Manouchehri A, Haugh AM, Quach HT, Balko JM, Lebrun-Vignes B et al (2019) Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer 7(1):134","journal-title":"J Immunother Cancer"},{"issue":"19","key":"7896_CR33","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.2217\/fon-2020-1222","volume":"17","author":"GP Sonpavde","year":"2021","unstructured":"Sonpavde GP, Grivas P, Lin Y, Hennessy D, Hunt JD (2021) Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials. Future Oncol 17(19):2545\u20132558","journal-title":"Future Oncol"},{"key":"7896_CR34","volume":"50","author":"L Plomp","year":"2025","unstructured":"Plomp L, Chassepot H, Psimaras D, Maisonobe T, Mensi E, Leonard-Louis S et al (2025) Features of myositis and myasthenia gravis in patients treated with immune checkpoint inhibitors: a multicentric, retrospective cohort study. The Lancet Regional Health 50:101192","journal-title":"The Lancet Regional Health"},{"issue":"6","key":"7896_CR35","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1136\/ard-2022-223792","volume":"82","author":"I Pinal-Fernandez","year":"2023","unstructured":"Pinal-Fernandez I, Quintana A, Milisenda JC, Casal-Dominguez M, Mu\u00f1oz-Braceras S, Derfoul A et al (2023) Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis. Ann Rheum Dis 82(6):829\u201336","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"7896_CR36","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","volume":"14","author":"NJ McHugh","year":"2018","unstructured":"McHugh NJ, Tansley SL (2018) Autoantibodies in myositis. Nat Rev Rheumatol 14(5):290\u2013302","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"7896_CR37","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","volume":"7","author":"IE Lundberg","year":"2021","unstructured":"Lundberg IE, Fujimoto M, Vencovsky J, Aggarwal R, Holmqvist M, Christopher-Stine L et al (2021) Idiopathic inflammatory myopathies. Nat Rev Dis Primers 7(1):86","journal-title":"Nat Rev Dis Primers"},{"key":"7896_CR38","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jaut.2019.03.005","volume":"100","author":"M Seki","year":"2019","unstructured":"Seki M, Uruha A, Ohnuki Y, Kamada S, Noda T, Onda A et al (2019) Inflammatory myopathy associated with PD-1 inhibitors. J Autoimmun 100:105\u201313","journal-title":"J Autoimmun"},{"issue":"7","key":"7896_CR39","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00415-025-13181-2","volume":"272","author":"L M\u00fcller-Jensen","year":"2025","unstructured":"M\u00fcller-Jensen L, M\u00f6hn N, Skripuletz T, Carl S, Thomas J, Grote-Levi L et al (2025) Complement activation profiles in patients with immune checkpoint inhibitor-associated neuromuscular immune-related adverse events. J Neurol 272(7):459","journal-title":"J Neurol"},{"issue":"2","key":"7896_CR40","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s13760-020-01282-w","volume":"120","author":"L Vermeulen","year":"2020","unstructured":"Vermeulen L, Depuydt CE, Weckx P, Bechter O, Van Damme P, Thal DR et al (2020) Myositis as a neuromuscular complication of immune checkpoint inhibitors. Acta Neurol Belg 120(2):355\u2013364","journal-title":"Acta Neurol Belg"},{"issue":"5","key":"7896_CR41","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/cvr\/cvz025","volume":"115","author":"N Grabie","year":"2019","unstructured":"Grabie N, Lichtman AH, Padera R (2019) T cell checkpoint regulators in the heart. Cardiovasc Res 115(5):869\u2013877","journal-title":"Cardiovasc Res"},{"issue":"10","key":"7896_CR42","doi-asserted-by":"crossref","first-page":"4876","DOI":"10.4049\/jimmunol.1200389","volume":"188","author":"ML Tarrio","year":"2012","unstructured":"Tarrio ML, Grabie N, Bu DX, Sharpe AH, Lichtman AH (2012) PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. J Immunol 188(10):4876\u20134884","journal-title":"J Immunol"},{"issue":"18","key":"7896_CR43","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1161\/CIRCULATIONAHA.107.709360","volume":"116","author":"N Grabie","year":"2007","unstructured":"Grabie N, Gotsman I, DaCosta R, Pang H, Stavrakis G, Butte MJ et al (2007) Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart. Circulation 116(18):2062\u201371","journal-title":"Circulation"},{"issue":"1","key":"7896_CR44","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cellimm.2014.05.006","volume":"290","author":"S Dai","year":"2014","unstructured":"Dai S, Jia R, Zhang X, Fang Q, Huang L (2014) The PD-1\/PD-Ls pathway and autoimmune diseases. Cell Immunol 290(1):72\u201379","journal-title":"Cell Immunol"},{"issue":"10","key":"7896_CR45","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","volume":"74","author":"JC Kao","year":"2017","unstructured":"Kao JC, Liao B, Markovic SN, Klein CJ, Naddaf E, Staff NP et al (2017) Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol 74(10):1216\u20131222","journal-title":"JAMA Neurol"},{"issue":"1","key":"7896_CR46","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1186\/s12885-025-13868-9","volume":"25","author":"K Wei","year":"2025","unstructured":"Wei K, Sun T, Feng X, Chen Y, Liu Q, Tang H (2025) PD-1\/L1 immune checkpoint inhibitors for KRAS-mutant non-small cell lung cancer: a multicenter retrospective real-world study. BMC Cancer 25(1):444","journal-title":"BMC Cancer"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07896-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07896-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07896-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T09:53:31Z","timestamp":1771581211000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07896-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,27]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["7896"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07896-w","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,27]]},"assertion":[{"value":"31 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}